Morgan Dempsey Capital Management LLC reduced its position in shares of Mednax, Inc (NYSE:MD) by 3.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,192 shares of the company’s stock after selling 78 shares during the period. Morgan Dempsey Capital Management LLC’s holdings in Mednax were worth $132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Mednax by 5,766.0% in the first quarter. BlackRock Inc. now owns 8,229,340 shares of the company’s stock valued at $570,952,000 after buying an additional 8,089,052 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Mednax by 144.1% in the first quarter. Schroder Investment Management Group now owns 1,734,697 shares of the company’s stock valued at $120,458,000 after buying an additional 1,024,048 shares during the last quarter. Longview Partners Guernsey LTD increased its position in shares of Mednax by 27.4% in the first quarter. Longview Partners Guernsey LTD now owns 4,555,631 shares of the company’s stock valued at $316,070,000 after buying an additional 980,081 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Mednax by 62.9% in the first quarter. Victory Capital Management Inc. now owns 1,977,791 shares of the company’s stock valued at $137,219,000 after buying an additional 763,633 shares during the last quarter. Finally, Clearbridge Investments LLC increased its position in shares of Mednax by 33.1% in the first quarter. Clearbridge Investments LLC now owns 2,048,277 shares of the company’s stock valued at $142,109,000 after buying an additional 508,863 shares during the last quarter.

Mednax, Inc (MD) opened at 42.10 on Friday. Mednax, Inc has a 1-year low of $41.90 and a 1-year high of $72.13. The company has a 50-day moving average price of $54.64 and a 200 day moving average price of $61.63. The firm has a market capitalization of $3.88 billion, a P/E ratio of 13.41 and a beta of 0.40.

Mednax (NYSE:MD) last issued its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.04. The firm had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. Mednax’s revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.03 earnings per share. Analysts expect that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/morgan-dempsey-capital-management-llc-has-132000-position-in-mednax-inc-md/1473523.html.

Several research analysts have recently weighed in on MD shares. ValuEngine downgraded Mednax from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. TheStreet downgraded Mednax from a “b-” rating to a “c+” rating in a research note on Tuesday, May 16th. Bank of America Corporation downgraded Mednax from a “buy” rating to an “underperform” rating in a research note on Thursday, May 4th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $53.00 target price (up from $50.00) on shares of Mednax in a research note on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company’s stock. Mednax currently has a consensus rating of “Hold” and an average target price of $64.00.

In related news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the transaction, the director now directly owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of Mednax stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the transaction, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.